Burri Lena, Johnsen Line
Aker BioMarine Antarctic AS, Fjordalléen 16, NO-0115 Oslo, Norway.
Nutrients. 2015 May 7;7(5):3300-21. doi: 10.3390/nu7053300.
Many animal studies have been performed with krill oil (KO) and this review aims to summarize their findings and give insight into the mechanism of action of KO. Animal models that have been used in studies with KO include obesity, depression, myocardial infarction, chronic low-grade and ulcerative inflammation and are described in detail. Moreover, studies with KO in the form of krill powder (KP) and krill protein concentrate (KPC) as a mix of lipids and proteins are mentioned and compared to the effects of KO. In addition, differences in tissue uptake of the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), when delivered in either phospholipid or triglyceride form, are addressed and the differential impact the delivery form has on gene expression profiles is explained. In our outlook, we try to highlight the potential of KO and KP supplementation in clinical settings and discuss health segments that have a high potential of showing krill product specific health benefits and warrant further clinical investigations.
已经对磷虾油(KO)进行了许多动物研究,本综述旨在总结其研究结果,并深入了解KO的作用机制。在KO研究中使用的动物模型包括肥胖、抑郁、心肌梗死、慢性低度和溃疡性炎症,并将进行详细描述。此外,还提到了以磷虾粉(KP)和磷虾蛋白浓缩物(KPC)形式存在的KO研究,它们是脂质和蛋白质的混合物,并与KO的效果进行了比较。此外,还讨论了长链ω-3多不饱和脂肪酸二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)以磷脂或甘油三酯形式递送时在组织摄取方面的差异,并解释了递送形式对基因表达谱的不同影响。在展望部分,我们试图强调在临床环境中补充KO和KP的潜力,并讨论极有可能显示磷虾产品特定健康益处且值得进一步临床研究的健康领域。